# Catamaran Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/catamaran-bio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.catamaranbio.com
- Total disclosed funding: $42M
- Latest round: Series A (Nov 23, 2020)
- Investors on record: 5

## About

Catamaran Bio, Inc. is a biotechnology company that specializes in innovative cell therapies, focusing on engineering Natural Killer (NK) cell therapies to combat solid tumors and various cancers.Founded in 2020 and headquartered in Cambridge, US, Catamaran Bio, Inc. is dedicated to the development of advanced cell therapies. The company raised USD 42.00 mn in Series A funding on November 23, 2020, co-led by Lightstone Ventures and Sofinnova Partners, with participation from Astellas Venture Management, Takeda Ventures, and returning investor SV Health Investors. The founders, Branden Moriarity and Kevin Pojasek, bring extensive experience to the company, while Alvin Shih serves as CEO.Catamaran Bio specializes in innovative cell therapies, primarily focusing on engineering Natural Killer (NK) cell therapies aimed at treating solid tumors and various types of cancer. Their flagship offering is the TAILWIND® platform, a proprietary suite of technologies designed to safely and effectively engineer, expand, and process NK cells into allogeneic CAR-NK cell therapy products. The therapies utilize the innate cancer-fighting abilities of NK cells combined with advanced synthetic biology and non-viral engineering techniques, targeting healthcare providers and cancer treatment centers in North America and Europe.Catamaran Bio generates revenue primarily through strategic partnerships and collaborations focused on the development and manufacturing of its CAR-NK cell therapies. The company engages in B2B transactions with pharmaceutical companies, academic institutions, and healthcare providers, utilizing licensing agreements and collaborative research contracts that may involve milestones and royalties. The revenue model reflects the specialized nature of the products and the market demand for effective cancer treatments, with the TAILWIND® platform being central to these transactions.Catamaran Bio plans to utilize the USD 42.00 mn from its Series A funding to further develop its product pipeline and expand into new markets. The company aims to enhance its TAILWIND® platform and introduce new cell therapies targeting specific cancers within the next two years. Additionally, Catamaran Bio intends to enter European markets by 2023, capitalizing on the growing demand for innovative cancer treatments.

## Funding rounds

- Series A, Nov 23, 2020, $42M — Sofinnova Partners, Astellas Venture Management, SV Health Investors, Takeda Ventures, Lightstone Ventures

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A